A new report from CNET provides the latest on available monoclonal antibody treatments. With Ba.2 or “stealth omicron” accounting for more than 70% of COVID cases in the US, it helps to have the latest information on these potentially life-saving treatments.
In March, GlaxoSmithKline said the FDA found that its treatment sotrovimab“unlikely” to be effective against the BA.2 variant. The companies added that they are preparing data on a higher dose of sotrovimab that may work against BA.2.
Sotrovimab, like other monoclonal antibodies, has been used as treatment for COVID-19 in people most at risk for severe COVID-19 disease or hospitalization in the early days of their symptoms.TrendingBREAKING: Trump Sues Hillary Clinton, Democrats for Russian Collusion Allegations
Bebtelovimab, made by Eli Lilly, is a monoclonal antibody still authorized for use in patients 12 and up who have mild or moderate COVID-19 and are at high risk for severe disease. The antibody should be used when other treatments for high-risk patients are either unavailable or inappropriate, and given within the first seven days of COVID-19 symptoms, the FDA said.
According to the FDA, “Bebtelovimab is not authorized for patients who are hospitalized due to COVID-19 or require oxygen therapy due to COVID-19. Treatment with bebtelovimab has not been studied in patients hospitalized due to COVID-19.”